Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Obesity

Mapped: NHS patients facing postcode lottery for weight-loss jab Mounjaro

It’s estimated that 3.4 million people in the UK could benefit from taking a weight-loss jab like Mounjaro

The Independent UK

‘No place in children’s hands’: under-16s in England to be banned from buying energy drinks

Government to ban sale of energy drinks with more than 150mg of caffeine, citing concerns over obesity and lack of concentration

The Guardian - UK

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

Benzinga

How more weight-loss jabs could save the country £53 billion a year

IN FULL

The Independent UK

True cost of the UK’s obesity crisis revealed – and how weight-loss jabs could be the answer

SPECIAL REPORT: The UK has an obesity epidemic, with levels having doubled since the 1990s. Could increasing the rollout of weight-loss drugs ease the burden on the overstretched NHS? Alicja Hagopian and Rebecca Thomas report

The Independent UK

Weight-loss drugs are a quick fix with long-term results

THE INDEPENDENT VIEW: Editorial: For those able to take them, weight-loss drugs can offer startling results in improved quality of life, and in relieving the pressure on the NHS and the British economy

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

OPINION - The soaring price of weight loss drugs could derail the NHS's obesity plan – unless they take this action

The list price for the most popular and effective weight loss injection (Mounjaro) in the UK has risen by almost three times, from £122 to £330 a month for the highest dose, as of September 1.

Evening Standard

Ozempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We Know

Scientists test OKV-119, a six-month implant dubbed 'Ozempup', as a new Ozempic for pets to fight obesity in cats and dogs amid rising pet health risks.

International Business Times UK

Deadline set for manufacturers to cut sugar and salt in baby food

New data shows that more than two thirds of children aged 18 months to three years are eating too much sugar

The Independent UK

Manufacturers given 18 months to cut sugar and salt in baby food products

New labelling guidelines will also help parents make informed choices about what they feed their children.

Evening Standard

Obesity has a serious impact on health – it shortened my mum’s life

Letter: Blaming the patriarchy, fatphobia or big pharma doesn’t reduce the risks of being overweight, says Frances Knight

The Guardian - UK

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Palantir, AMD, Oracle, Viking And Nvidia: Why These 5 Stocks Are On Investors' Radars Today

U.S. stock indices closed mixed on Tuesday, with the Dow Jones Industrial Average edging up 0.02% to 44,922.27. The SP 500 slipped 0.6% to 6,411.37, while the Nasdaq saw a steeper drop, tumbling nearly 1.5% to 21,314.95.These are the top stocks that gained the attention of retail traders and investors…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

Benzinga

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Benzinga

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

The Guardian - UK

Puppy fat implants: are our pets next in line for weight-loss drugs?

A biotech firm has announced trials for a dog implant that mimics the drugs taken by humans to help tackle obesity

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

The Conversation

Ultra-processed foods might not be the real villain in our diets – here’s what our research found

Ultra-processed foods (UPFs) have become public enemy number one in nutrition debates. From dementia to obesity and an epidemic of “food addiction”, these factory-made products, including crisps, ready meals, fizzy drinks and packaged snacks, are blamed for a wide range of modern health problems. Some experts argue that they’re “specifically…

Benzinga

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

Benzinga

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

The Guardian - UK

Wolverhampton cemetery’s extra fee for wider graves criticised as ‘fat tax’

Council says measure at Danescourt cemetery in Tettenhall is in response to increase in obesity levels in city

Benzinga

Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens

Vacations are on hold, dinners out skipped, and doses stretched — all so patients can keep taking weight-loss drugs like Wegovy and Zepbound as insurers pull back coverage in 2025.

Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.